How much of Gilead's 2005 revenue came from its HIV franchise, and how concentrated is it?

HIV products generated $1.39 billion, or 69% of total 2005 revenues and 77% of product sales. Viread and Truvada accounted for 56% and 41% of HIV sales, respectively. The company itself acknowledges that substantially all of its revenue depends on a limited number of products, so any erosion in nucleoside-based HIV therapy or competitive share loss would materially affect results.

Was the 2005 earnings growth driven by recurring operations?

Partly. Net income included an $80.7 million one-time royalty recognition from the Roche Tamiflu settlement and a $25.1 million tax benefit tied to repatriating foreign earnings. Excluding these items, earnings still grew substantially on product sales growth, but the headline increase overstates the recurring rate of improvement. Operating income was $1.11 billion versus $631.7 million in 2004.

What are the main risks to Gilead's revenue outlook?

Key risks include generic and new competition (GSK's fixed-dose combinations, BMS's Baraclude against Hepsera, and new lipid AmBisome formulations), pricing pressure from Medicare Part D and European governments, compulsory licensing in Brazil and developing countries, and slow payment from Southern European governments, where $156.9 million of receivables were past due at year-end. The company also depends on partners such as Roche for Tamiflu royalties and on a single supplier for several key materials.

How is Gilead's balance sheet positioned after the 2005 transactions?

Total assets grew to $3.76 billion and stockholders' equity to $3.03 billion. Cash and marketable securities were $2.32 billion against $300 million of term loan debt, which carries LIBOR-based interest and quarterly $15 million amortization beginning in March 2006. The company also capitalized $341.3 million of prepaid royalties from the Emory emtricitabine royalty buyout, which will be amortized into cost of goods sold.

What should investors expect for 2006 expenses and margins?

Management expects R&D expenses to increase over 2005's $277.7 million, SG&A to rise from $379.2 million due to Truvada launch costs and commercial expansion, and product gross margin to remain roughly consistent with 2005's 86%. Share-based compensation under SFAS 123R, adopted January 1, 2006, is estimated to reduce diluted EPS by about $0.15 to $0.17. A potential U.S. launch of the Truvada-Sustiva triple product would lower the gross margin percentage but not net profit, since Gilead consolidates 100% of its joint venture.

GILD 10-K FY2005 Annual Report — Revenue, Net Income, EPS

01—Abstract

Summary

Summary of the 10-K filed March 3, 2006. Cited figures are marked; the original filing is the authoritative source.

Gilead Sciences' 2005 10-K shows a company in strong commercial ascent.

Total revenues rose 53% to $2.03 billion^a in 2005 (from $1.32 billion), and net income reached $813.9 million, or $1.72 diluted EPS, versus $449.4 million in 2004. Growth was driven by HIV franchise sales of $1.39 billion (69% of total revenues), with Truvada launching in Europe and the U.S. Hepsera and AmBisome also contributed. Profitability was boosted by a one-time $80.7 million Roche royalty settlement and a $25.1 million tax benefit from the AJCA repatriation, so underlying earnings growth is somewhat lower than headline figures suggest.

Product gross margin remained high at 86%. The balance sheet strengthened substantially. Cash and marketable securities reached $2.32 billion^b, up 85%, and operating cash flow was $715.1 million.

Gilead also took on a $300 million^c term loan and a $200 million revolver, used largely to repatriate foreign earnings, and paid $525 million (its 65% share $341.3 million capitalized) to acquire the Emory emtricitabine royalty interest alongside Royalty Pharma. Key risks for investors are concentration and reimbursement. Substantially all revenue comes from a handful of HIV and related products, Viread and Truvada alone generated 97% of HIV sales, and roughly 89% of U.S. product sales go to three wholesalers.

Competition from GSK, BMS and generics, European government reimbursement pressure and delayed payments from Greece, Italy, Portugal and Spain ($156.9 million^d past due), and Medicare Part D changes all pose downside. Management guided 2006 HIV product sales of $1.675-1.750 billion and expects SFAS 123R to reduce EPS by roughly $0.15-0.17.

02—Key points

Key Highlights

Total revenues grew 53% to $2.03 billion in 2005, with product sales of $1.81 billion (up 46%) and royalty revenue of $196.9 million, including $80.7 million from the Roche dispute resolution.
Net income rose to $813.9 million ($1.72 diluted EPS) from $449.4 million ($0.99) in 2004, aided by a $25.1 million one-time tax benefit from AJCA repatriation.
HIV products generated $1.39 billion (69% of revenues), led by Viread at $778.8 million (flat year over year) and Truvada, which surged to $567.8 million from $67.9 million as European launches began.
Hepsera sales rose 66% to $186.5 million, and AmBisome grew 4% to $220.8 million; product gross margin held at 86%.
Cash, cash equivalents and marketable securities reached $2.32 billion (up 85%), with operating cash flow of $715.1 million, supported by a $300 million term loan and a $200 million undrawn revolver.
Concentration risk is high: nearly all revenue depends on HIV nucleoside products, about 89% of U.S. product sales go to three wholesalers, and European receivables from government-supported customers remain a collection risk.
2006 guidance calls for HIV product sales of $1.675-1.750 billion, AmBisome of $205-215 million, Hepsera of $200-210 million, and SFAS 123R expense of about $0.15-0.17 per diluted share.

03—Questions

Frequently Asked Questions

How much of Gilead's 2005 revenue came from its HIV franchise, and how concentrated is it?
HIV products generated $1.39 billion, or 69% of total 2005 revenues and 77% of product sales. Viread and Truvada accounted for 56% and 41% of HIV sales, respectively. The company itself acknowledges that substantially all of its revenue depends on a limited number of products, so any erosion in nucleoside-based HIV therapy or competitive share loss would materially affect results.
Was the 2005 earnings growth driven by recurring operations?
Partly. Net income included an $80.7 million one-time royalty recognition from the Roche Tamiflu settlement and a $25.1 million tax benefit tied to repatriating foreign earnings. Excluding these items, earnings still grew substantially on product sales growth, but the headline increase overstates the recurring rate of improvement. Operating income was $1.11 billion versus $631.7 million in 2004.
What are the main risks to Gilead's revenue outlook?
Key risks include generic and new competition (GSK's fixed-dose combinations, BMS's Baraclude against Hepsera, and new lipid AmBisome formulations), pricing pressure from Medicare Part D and European governments, compulsory licensing in Brazil and developing countries, and slow payment from Southern European governments, where $156.9 million of receivables were past due at year-end. The company also depends on partners such as Roche for Tamiflu royalties and on a single supplier for several key materials.
How is Gilead's balance sheet positioned after the 2005 transactions?
Total assets grew to $3.76 billion and stockholders' equity to $3.03 billion. Cash and marketable securities were $2.32 billion against $300 million of term loan debt, which carries LIBOR-based interest and quarterly $15 million amortization beginning in March 2006. The company also capitalized $341.3 million of prepaid royalties from the Emory emtricitabine royalty buyout, which will be amortized into cost of goods sold.
What should investors expect for 2006 expenses and margins?
Management expects R&D expenses to increase over 2005's $277.7 million, SG&A to rise from $379.2 million due to Truvada launch costs and commercial expansion, and product gross margin to remain roughly consistent with 2005's 86%. Share-based compensation under SFAS 123R, adopted January 1, 2006, is estimated to reduce diluted EPS by about $0.15 to $0.17. A potential U.S. launch of the Truvada-Sustiva triple product would lower the gross margin percentage but not net profit, since Gilead consolidates 100% of its joint venture.

04—Continue

← View all 10-K filings